nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—POR—malignant glioma	0.882	1	CbGaD
Nilutamide—Interstitial pneumonia—Temozolomide—malignant glioma	0.0025	0.0462	CcSEcCtD
Nilutamide—Enzalutamide—CYP2B6—malignant glioma	0.00236	1	CrCbGaD
Nilutamide—Interstitial lung disease—Carmustine—malignant glioma	0.00177	0.0327	CcSEcCtD
Nilutamide—Interstitial lung disease—Temozolomide—malignant glioma	0.00171	0.0316	CcSEcCtD
Nilutamide—Lung disorder—Temozolomide—malignant glioma	0.00171	0.0316	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00121	0.0224	CcSEcCtD
Nilutamide—Gynaecomastia—Carmustine—malignant glioma	0.00112	0.0207	CcSEcCtD
Nilutamide—Abnormal vision—Carmustine—malignant glioma	0.00109	0.0202	CcSEcCtD
Nilutamide—Abnormal vision—Temozolomide—malignant glioma	0.00105	0.0195	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00101	0.0187	CcSEcCtD
Nilutamide—Hot flush—Temozolomide—malignant glioma	0.000938	0.0173	CcSEcCtD
Nilutamide—Menopausal symptoms—Temozolomide—malignant glioma	0.000929	0.0172	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000908	0.0168	CcSEcCtD
Nilutamide—Dry skin—Temozolomide—malignant glioma	0.000804	0.0149	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00079	0.0146	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000773	0.0143	CcSEcCtD
Nilutamide—Hyperglycaemia—Carmustine—malignant glioma	0.000708	0.0131	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000704	0.013	CcSEcCtD
Nilutamide—Pneumonia—Carmustine—malignant glioma	0.000703	0.013	CcSEcCtD
Nilutamide—Erectile dysfunction—Temozolomide—malignant glioma	0.000698	0.0129	CcSEcCtD
Nilutamide—Depression—Carmustine—malignant glioma	0.000697	0.0129	CcSEcCtD
Nilutamide—Weight decreased—Temozolomide—malignant glioma	0.000686	0.0127	CcSEcCtD
Nilutamide—Hyperglycaemia—Temozolomide—malignant glioma	0.000684	0.0126	CcSEcCtD
Nilutamide—Urinary tract infection—Carmustine—malignant glioma	0.00068	0.0126	CcSEcCtD
Nilutamide—Pneumonia—Temozolomide—malignant glioma	0.00068	0.0126	CcSEcCtD
Nilutamide—Depression—Temozolomide—malignant glioma	0.000674	0.0125	CcSEcCtD
Nilutamide—Urinary tract infection—Temozolomide—malignant glioma	0.000657	0.0122	CcSEcCtD
Nilutamide—Hypoaesthesia—Carmustine—malignant glioma	0.000625	0.0116	CcSEcCtD
Nilutamide—Oedema peripheral—Carmustine—malignant glioma	0.000618	0.0114	CcSEcCtD
Nilutamide—Visual impairment—Carmustine—malignant glioma	0.000605	0.0112	CcSEcCtD
Nilutamide—Hypoaesthesia—Temozolomide—malignant glioma	0.000604	0.0112	CcSEcCtD
Nilutamide—Urinary tract disorder—Temozolomide—malignant glioma	0.000599	0.0111	CcSEcCtD
Nilutamide—Oedema peripheral—Temozolomide—malignant glioma	0.000598	0.0111	CcSEcCtD
Nilutamide—Urethral disorder—Temozolomide—malignant glioma	0.000595	0.011	CcSEcCtD
Nilutamide—Visual impairment—Temozolomide—malignant glioma	0.000585	0.0108	CcSEcCtD
Nilutamide—Alopecia—Carmustine—malignant glioma	0.000555	0.0103	CcSEcCtD
Nilutamide—Alopecia—Temozolomide—malignant glioma	0.000536	0.00992	CcSEcCtD
Nilutamide—Back pain—Carmustine—malignant glioma	0.000529	0.00978	CcSEcCtD
Nilutamide—Back pain—Temozolomide—malignant glioma	0.000511	0.00945	CcSEcCtD
Nilutamide—Anaemia—Carmustine—malignant glioma	0.000505	0.00934	CcSEcCtD
Nilutamide—Ill-defined disorder—Temozolomide—malignant glioma	0.00049	0.00907	CcSEcCtD
Nilutamide—Leukopenia—Carmustine—malignant glioma	0.000489	0.00905	CcSEcCtD
Nilutamide—Anaemia—Temozolomide—malignant glioma	0.000488	0.00903	CcSEcCtD
Nilutamide—Malaise—Temozolomide—malignant glioma	0.000476	0.00881	CcSEcCtD
Nilutamide—Leukopenia—Temozolomide—malignant glioma	0.000473	0.00875	CcSEcCtD
Nilutamide—Hypertension—Carmustine—malignant glioma	0.000472	0.00873	CcSEcCtD
Nilutamide—Chest pain—Carmustine—malignant glioma	0.000465	0.00861	CcSEcCtD
Nilutamide—Cough—Temozolomide—malignant glioma	0.000461	0.00853	CcSEcCtD
Nilutamide—Hypertension—Temozolomide—malignant glioma	0.000456	0.00844	CcSEcCtD
Nilutamide—Oedema—Carmustine—malignant glioma	0.000446	0.00825	CcSEcCtD
Nilutamide—Discomfort—Temozolomide—malignant glioma	0.000444	0.00822	CcSEcCtD
Nilutamide—Dry mouth—Temozolomide—malignant glioma	0.00044	0.00814	CcSEcCtD
Nilutamide—Oedema—Temozolomide—malignant glioma	0.000431	0.00797	CcSEcCtD
Nilutamide—Anorexia—Carmustine—malignant glioma	0.000425	0.00787	CcSEcCtD
Nilutamide—Hyperhidrosis—Temozolomide—malignant glioma	0.000417	0.00771	CcSEcCtD
Nilutamide—Anorexia—Temozolomide—malignant glioma	0.000411	0.0076	CcSEcCtD
Nilutamide—Insomnia—Carmustine—malignant glioma	0.000403	0.00746	CcSEcCtD
Nilutamide—Paraesthesia—Carmustine—malignant glioma	0.000401	0.00741	CcSEcCtD
Nilutamide—Dyspnoea—Carmustine—malignant glioma	0.000398	0.00736	CcSEcCtD
Nilutamide—Insomnia—Temozolomide—malignant glioma	0.00039	0.00721	CcSEcCtD
Nilutamide—Decreased appetite—Carmustine—malignant glioma	0.000388	0.00717	CcSEcCtD
Nilutamide—Paraesthesia—Temozolomide—malignant glioma	0.000387	0.00716	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Carmustine—malignant glioma	0.000385	0.00712	CcSEcCtD
Nilutamide—Dyspnoea—Temozolomide—malignant glioma	0.000384	0.00711	CcSEcCtD
Nilutamide—Constipation—Carmustine—malignant glioma	0.000381	0.00706	CcSEcCtD
Nilutamide—Pain—Carmustine—malignant glioma	0.000381	0.00706	CcSEcCtD
Nilutamide—Dyspepsia—Temozolomide—malignant glioma	0.000379	0.00702	CcSEcCtD
Nilutamide—Decreased appetite—Temozolomide—malignant glioma	0.000375	0.00693	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000372	0.00688	CcSEcCtD
Nilutamide—Pain—Temozolomide—malignant glioma	0.000369	0.00682	CcSEcCtD
Nilutamide—Constipation—Temozolomide—malignant glioma	0.000369	0.00682	CcSEcCtD
Nilutamide—Feeling abnormal—Carmustine—malignant glioma	0.000368	0.0068	CcSEcCtD
Nilutamide—Gastrointestinal pain—Carmustine—malignant glioma	0.000365	0.00675	CcSEcCtD
Nilutamide—Feeling abnormal—Temozolomide—malignant glioma	0.000355	0.00657	CcSEcCtD
Nilutamide—Abdominal pain—Carmustine—malignant glioma	0.000353	0.00652	CcSEcCtD
Nilutamide—Body temperature increased—Carmustine—malignant glioma	0.000353	0.00652	CcSEcCtD
Nilutamide—Gastrointestinal pain—Temozolomide—malignant glioma	0.000352	0.00652	CcSEcCtD
Nilutamide—Body temperature increased—Temozolomide—malignant glioma	0.000341	0.0063	CcSEcCtD
Nilutamide—Abdominal pain—Temozolomide—malignant glioma	0.000341	0.0063	CcSEcCtD
Nilutamide—Asthenia—Carmustine—malignant glioma	0.00032	0.00592	CcSEcCtD
Nilutamide—Asthenia—Temozolomide—malignant glioma	0.000309	0.00572	CcSEcCtD
Nilutamide—Diarrhoea—Carmustine—malignant glioma	0.000305	0.00565	CcSEcCtD
Nilutamide—Pruritus—Temozolomide—malignant glioma	0.000305	0.00564	CcSEcCtD
Nilutamide—Dizziness—Carmustine—malignant glioma	0.000295	0.00546	CcSEcCtD
Nilutamide—Diarrhoea—Temozolomide—malignant glioma	0.000295	0.00546	CcSEcCtD
Nilutamide—Dizziness—Temozolomide—malignant glioma	0.000285	0.00527	CcSEcCtD
Nilutamide—Vomiting—Carmustine—malignant glioma	0.000284	0.00525	CcSEcCtD
Nilutamide—Rash—Carmustine—malignant glioma	0.000281	0.0052	CcSEcCtD
Nilutamide—Dermatitis—Carmustine—malignant glioma	0.000281	0.0052	CcSEcCtD
Nilutamide—Headache—Carmustine—malignant glioma	0.000279	0.00517	CcSEcCtD
Nilutamide—Vomiting—Temozolomide—malignant glioma	0.000274	0.00507	CcSEcCtD
Nilutamide—Rash—Temozolomide—malignant glioma	0.000272	0.00503	CcSEcCtD
Nilutamide—Dermatitis—Temozolomide—malignant glioma	0.000272	0.00502	CcSEcCtD
Nilutamide—Headache—Temozolomide—malignant glioma	0.00027	0.005	CcSEcCtD
Nilutamide—Nausea—Carmustine—malignant glioma	0.000265	0.0049	CcSEcCtD
Nilutamide—Nausea—Temozolomide—malignant glioma	0.000256	0.00474	CcSEcCtD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.000234	0.00375	CbGpPWpGaD
Nilutamide—CYP2C8—Arachidonic acid metabolism—PTGS1—malignant glioma	0.000233	0.00374	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—NCOR1—malignant glioma	0.00023	0.00369	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—PML—malignant glioma	0.000225	0.00361	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.000221	0.00356	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	0.00022	0.00354	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—PTK2—malignant glioma	0.000218	0.0035	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	0.000216	0.00347	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000215	0.00345	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—NCOR1—malignant glioma	0.000213	0.00342	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.000213	0.00342	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	0.000209	0.00335	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—PTGS1—malignant glioma	0.000208	0.00333	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—malignant glioma	0.000205	0.00328	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.000202	0.00324	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000192	0.00308	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—NTRK2—malignant glioma	0.000191	0.00307	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—YWHAE—malignant glioma	0.000191	0.00307	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—PTGS1—malignant glioma	0.000189	0.00304	CbGpPWpGaD
Nilutamide—AR—Regulation of Androgen receptor activity—MDM2—malignant glioma	0.000189	0.00303	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	0.000186	0.00299	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000175	0.00281	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—CDKN2A—malignant glioma	0.000174	0.00279	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CAV1—malignant glioma	0.000174	0.00279	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—malignant glioma	0.000172	0.00277	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—PIK3CA—malignant glioma	0.000172	0.00276	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	0.00017	0.00273	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000163	0.00262	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—GJA1—malignant glioma	0.000157	0.00252	CbGpPWpGaD
Nilutamide—AR—Notch-mediated HES/HEY network—STAT3—malignant glioma	0.000156	0.00251	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—malignant glioma	0.000153	0.00245	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRCA2—malignant glioma	0.000148	0.00238	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000145	0.00234	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—AKT1—malignant glioma	0.00014	0.00225	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—malignant glioma	0.00014	0.00225	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—HES1—malignant glioma	0.000137	0.0022	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000133	0.00213	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	0.000132	0.00213	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP2B6—malignant glioma	0.000132	0.00212	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP2B6—malignant glioma	0.00013	0.00209	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—malignant glioma	0.000127	0.00204	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000126	0.00202	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—MDM2—malignant glioma	0.000125	0.002	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	0.000123	0.00198	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	0.000122	0.00196	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP2B6—malignant glioma	0.000118	0.00189	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP2B6—malignant glioma	0.000116	0.00186	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—malignant glioma	0.000115	0.00184	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—HIF1A—malignant glioma	0.000115	0.00184	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP2C18—malignant glioma	0.000114	0.00183	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP2C18—malignant glioma	0.000113	0.00181	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	0.000111	0.00178	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP2B6—malignant glioma	0.000107	0.00172	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BAD—malignant glioma	0.000107	0.00172	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP2B6—malignant glioma	0.000106	0.0017	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—PTEN—malignant glioma	0.000105	0.00168	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP2C18—malignant glioma	0.000102	0.00164	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP2C18—malignant glioma	0.000101	0.00162	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	9.9e-05	0.00159	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRAF—malignant glioma	9.74e-05	0.00156	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—malignant glioma	9.48e-05	0.00152	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—malignant glioma	9.39e-05	0.00151	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—STAT3—malignant glioma	9.37e-05	0.0015	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP2C18—malignant glioma	9.3e-05	0.00149	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTT1—malignant glioma	9.24e-05	0.00148	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP2C18—malignant glioma	9.17e-05	0.00147	CbGpPWpGaD
Nilutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—malignant glioma	8.91e-05	0.00143	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	8.87e-05	0.00142	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—PTGS1—malignant glioma	8.66e-05	0.00139	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	8.59e-05	0.00138	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—malignant glioma	8.52e-05	0.00137	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	8.49e-05	0.00136	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BCL2—malignant glioma	8.28e-05	0.00133	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTT1—malignant glioma	8.25e-05	0.00132	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—AKT1—malignant glioma	8.17e-05	0.00131	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MDM2—malignant glioma	8.16e-05	0.00131	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—malignant glioma	7.96e-05	0.00128	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NOTCH3—malignant glioma	7.86e-05	0.00126	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—PTGS1—malignant glioma	7.73e-05	0.00124	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTT1—malignant glioma	7.52e-05	0.00121	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CXCL8—malignant glioma	7.44e-05	0.00119	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CASP3—malignant glioma	7.31e-05	0.00117	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—malignant glioma	7.25e-05	0.00117	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	7.23e-05	0.00116	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL1B—malignant glioma	7.13e-05	0.00115	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CASP3—malignant glioma	7.12e-05	0.00114	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NOTCH2—malignant glioma	7.05e-05	0.00113	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—PTGS1—malignant glioma	7.05e-05	0.00113	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	6.86e-05	0.0011	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—PTEN—malignant glioma	6.86e-05	0.0011	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	6.76e-05	0.00109	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	6.74e-05	0.00108	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	6.67e-05	0.00107	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	6.52e-05	0.00105	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—malignant glioma	6.51e-05	0.00105	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RTEL1—malignant glioma	6.47e-05	0.00104	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTP1—malignant glioma	6.4e-05	0.00103	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTP1—malignant glioma	6.32e-05	0.00101	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—malignant glioma	6.2e-05	0.000996	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—CDKN2B—malignant glioma	6.06e-05	0.000973	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	6.05e-05	0.000972	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—malignant glioma	6.04e-05	0.00097	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—AKT1—malignant glioma	6.04e-05	0.00097	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RTEL1—malignant glioma	5.78e-05	0.000928	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NCOR1—malignant glioma	5.75e-05	0.000923	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTP1—malignant glioma	5.72e-05	0.000918	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—malignant glioma	5.7e-05	0.000916	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	5.69e-05	0.000913	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTP1—malignant glioma	5.64e-05	0.000905	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—malignant glioma	5.58e-05	0.000896	CbGpPWpGaD
Nilutamide—AR—Gene Expression—DNMT3B—malignant glioma	5.37e-05	0.000863	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—KRAS—malignant glioma	5.27e-05	0.000846	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RTEL1—malignant glioma	5.27e-05	0.000846	CbGpPWpGaD
Nilutamide—AR—Gene Expression—HIST1H3B—malignant glioma	5.22e-05	0.000838	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTP1—malignant glioma	5.21e-05	0.000837	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—malignant glioma	5.18e-05	0.000831	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTP1—malignant glioma	5.14e-05	0.000826	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	5.14e-05	0.000825	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	4.73e-05	0.000759	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—malignant glioma	4.68e-05	0.000752	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	4.63e-05	0.000743	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	4.62e-05	0.000742	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	4.48e-05	0.000719	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	4.4e-05	0.000707	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	4.37e-05	0.000701	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NOTCH1—malignant glioma	4.36e-05	0.000701	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	4.13e-05	0.000663	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARG—malignant glioma	4.12e-05	0.000661	CbGpPWpGaD
Nilutamide—AR—Gene Expression—H3F3A—malignant glioma	4.03e-05	0.000647	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	4.01e-05	0.000644	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	4e-05	0.000642	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—AKT1—malignant glioma	3.96e-05	0.000635	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	3.88e-05	0.000623	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NOTCH3—malignant glioma	3.78e-05	0.000608	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	3.77e-05	0.000605	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—COX8A—malignant glioma	3.72e-05	0.000597	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	3.64e-05	0.000585	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NOTCH2—malignant glioma	3.39e-05	0.000545	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	3.32e-05	0.000534	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—COX8A—malignant glioma	3.32e-05	0.000533	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	3.28e-05	0.000526	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ASMT—malignant glioma	3.16e-05	0.000508	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	3.09e-05	0.000496	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—COX8A—malignant glioma	3.03e-05	0.000486	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—BCAN—malignant glioma	2.97e-05	0.000478	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	2.97e-05	0.000477	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CDKN2B—malignant glioma	2.92e-05	0.000468	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ASMT—malignant glioma	2.82e-05	0.000453	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NCOR1—malignant glioma	2.77e-05	0.000444	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	2.76e-05	0.000443	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	2.71e-05	0.000435	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—BCAN—malignant glioma	2.65e-05	0.000426	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ASMT—malignant glioma	2.57e-05	0.000413	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	2.52e-05	0.000404	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—BCAN—malignant glioma	2.42e-05	0.000389	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—IDH2—malignant glioma	2.4e-05	0.000385	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—malignant glioma	2.35e-05	0.000377	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	2.26e-05	0.000363	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP2B6—malignant glioma	2.25e-05	0.000362	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—IDH2—malignant glioma	2.14e-05	0.000344	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NOTCH1—malignant glioma	2.1e-05	0.000337	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—IDH1—malignant glioma	2.06e-05	0.000331	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	2.02e-05	0.000324	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP2B6—malignant glioma	2.01e-05	0.000323	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SPHK1—malignant glioma	1.99e-05	0.00032	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARG—malignant glioma	1.98e-05	0.000318	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP2C18—malignant glioma	1.95e-05	0.000314	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—IDH2—malignant glioma	1.95e-05	0.000313	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.84e-05	0.000296	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—IDH1—malignant glioma	1.84e-05	0.000295	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.84e-05	0.000295	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP2B6—malignant glioma	1.83e-05	0.000295	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SPHK1—malignant glioma	1.78e-05	0.000286	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP2C18—malignant glioma	1.74e-05	0.00028	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.68e-05	0.00027	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—IDH1—malignant glioma	1.68e-05	0.000269	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.64e-05	0.000264	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SPHK1—malignant glioma	1.62e-05	0.000261	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.62e-05	0.00026	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP2C18—malignant glioma	1.59e-05	0.000255	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTT1—malignant glioma	1.58e-05	0.000254	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.5e-05	0.000241	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.5e-05	0.000241	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS1—malignant glioma	1.48e-05	0.000238	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.48e-05	0.000237	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.45e-05	0.000232	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTT1—malignant glioma	1.41e-05	0.000227	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—BCHE—malignant glioma	1.38e-05	0.000221	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.37e-05	0.000219	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC5A5—malignant glioma	1.36e-05	0.000218	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS1—malignant glioma	1.32e-05	0.000212	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.32e-05	0.000212	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.32e-05	0.000211	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTT1—malignant glioma	1.29e-05	0.000207	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.29e-05	0.000207	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.27e-05	0.000205	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—BCHE—malignant glioma	1.23e-05	0.000197	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC5A5—malignant glioma	1.21e-05	0.000195	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS1—malignant glioma	1.2e-05	0.000194	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.2e-05	0.000193	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.15e-05	0.000184	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.14e-05	0.000183	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—malignant glioma	1.13e-05	0.000182	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—BCHE—malignant glioma	1.12e-05	0.00018	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.11e-05	0.000178	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC5A5—malignant glioma	1.11e-05	0.000178	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTP1—malignant glioma	1.1e-05	0.000176	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CAT—malignant glioma	1.07e-05	0.000171	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.05e-05	0.000168	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.04e-05	0.000167	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NCOR1—malignant glioma	1.01e-05	0.000162	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.92e-06	0.000159	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTP1—malignant glioma	9.78e-06	0.000157	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CAT—malignant glioma	9.51e-06	0.000153	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.04e-06	0.000145	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NCOR1—malignant glioma	8.98e-06	0.000144	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTP1—malignant glioma	8.91e-06	0.000143	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CAT—malignant glioma	8.67e-06	0.000139	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CAV1—malignant glioma	8.2e-06	0.000132	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NCOR1—malignant glioma	8.19e-06	0.000132	CbGpPWpGaD
Nilutamide—AR—Gene Expression—AKT1—malignant glioma	7.84e-06	0.000126	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.84e-06	0.000126	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CG—malignant glioma	7.47e-06	0.00012	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CAV1—malignant glioma	7.32e-06	0.000118	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARG—malignant glioma	7.21e-06	0.000116	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7e-06	0.000112	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CAV1—malignant glioma	6.68e-06	0.000107	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CG—malignant glioma	6.67e-06	0.000107	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CD—malignant glioma	6.57e-06	0.000106	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARG—malignant glioma	6.44e-06	0.000103	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.38e-06	0.000102	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CG—malignant glioma	6.08e-06	9.77e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARG—malignant glioma	5.87e-06	9.43e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CD—malignant glioma	5.86e-06	9.42e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CB—malignant glioma	5.73e-06	9.2e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS2—malignant glioma	5.67e-06	9.11e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CD—malignant glioma	5.35e-06	8.59e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CB—malignant glioma	5.11e-06	8.21e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS2—malignant glioma	5.06e-06	8.13e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTEN—malignant glioma	4.95e-06	7.95e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CB—malignant glioma	4.66e-06	7.48e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS2—malignant glioma	4.62e-06	7.42e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTEN—malignant glioma	4.42e-06	7.09e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTEN—malignant glioma	4.03e-06	6.47e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CA—malignant glioma	3.49e-06	5.61e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CA—malignant glioma	3.12e-06	5e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKT1—malignant glioma	2.85e-06	4.58e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.84e-06	4.56e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKT1—malignant glioma	2.55e-06	4.09e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKT1—malignant glioma	2.32e-06	3.73e-05	CbGpPWpGaD
